#5: ARTIFICIAL ANTIBODIES
The majority of antibody drugs in clinical trials today have complex structures and high molecular weights, making them costly to manufacture.
Researchers at the Korea Advanced Institute of Science and Technology (KAIST) have made a simpler version of an antibody, called a repebody.
The artificial antibodies have a simpler structural backbone fused to a protein binding domain and can be mass produced in bacteria.
In a mouse model of non-small cell lung cancer, repebodies bound to their interleukin-6 target, leading to a reduction in tumor load.
#3D Printing #Australia #Biotechnology #China #Ebola #Fudan University #Gene Editing #India #Indian Institute of Technology Bombay #Innovation #Institute of Bioengineering and Nanotechnology #Japan #KAIST #Microfluidics #Nagasaki University #Sickle Cell Disease #Singapore #Solar Energy #South Korea #University of Otago #University of Wollongong #Wearable Technology
